基于犹他州人口数据库的前列腺癌长期治疗模式与泌尿系统不良事件:方法学框架与患者结局
本研究利用犹他州人口数据库(UPDB)构建方法学框架,回顾性匹配队列纳入1996-2023年确诊的局限性前列腺癌(PCa)患者36,482例及对照69,722例,中位随访8.0年和7.8年。结果显示,至20年时50%病例至少出现1次低级别泌尿系统不良事件(对照39%),15.1%出现高级别事件(对照6.7%),继发性泌尿系统恶性肿瘤风险为2.6倍。该框架可纳入常被国家数据库排除的年轻患者,支持长期生存研究。
要点
- UPDB框架可识别PCa患者并量化长期泌尿系统不良事件。
- 20年时低级别事件50% vs 39%,高级别事件15.1% vs 6.7%。
- 继发性泌尿系统恶性肿瘤风险为PCa患者的2.6倍。
核心结论
- 利用UPDB可全面长期评估多样化PCa患者的治疗相关发病率,包括常被国家数据集排除的年轻人群。
研究设计与样本
- 回顾性匹配队列研究,纳入UPDB中1996-2023年确诊的18-85岁局限性PCa男性,按年龄和性别2:1匹配对照。
- 排除既往泌尿系统不良事件、转移性疾病或数据缺失者;治疗分为9个标准组,泌尿系统不良事件按诊断和手术代码分低级别或高级别。
主要发现
- 近36%的PCa患者年龄小于65岁,这些患者本会被SEER-Medicare研究排除。
- 至20年时,50%的病例至少出现1次低级别诊断(对照39%),15.1%出现高级别诊断(对照6.7%)。
- PCa患者的继发性泌尿系统恶性肿瘤风险是对照的2.6倍。
临床怎么用
- 该框架支持更准确的生存研究,可指导预测建模以辅助患者咨询和治疗计划。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To develop and apply a framework using the Utah Population Database (UPDB) to identify PCa patients, characterize treatment patterns, and quantify long-term urologic adverse events (UAEs) given that prostate cancer (PCa) is a leading malignancy in men with high survival rates but limited data on long-term urologic morbidity. METHODS: We conducted a retrospective matched cohort study of men aged 18-85 with localized PCa diagnosed between 1996-2023 in the UPDB. Age- and sex-matched controls were selected 2:1. Exclusions included prior UAE, metastatic disease, or missing data. Treatments were classified into 9 standard groups, and UAEs were categorized as low- or high-grade using diagnosis and procedure codes. Temporal analyses were performed at 1, 5, 10, 15, and 20 years post-diagnosis. RESULTS: After exclusions, 36,482 cases and 69,722 controls were included (median follow-up: 8.0 and 7.8 years, respectively). Forty percent of cases and controls had a minimum 10-year follow-up after prostate cancer diagnosis. Nearly 36% of PCa patients were under age 65 and would have been excluded from SEER-Medicare studies. By 20 years, 50% of cases had at least 1 low-grade diagnosis (vs 39% controls) and 15.1% had a high-grade diagnosis (vs 6.7%). Secondary urologic malignancy risk was 2.6-fold higher in PCa patients. CONCLUSION: Leveraging the UPDB enables comprehensive, long-term evaluation of treatment-related morbidity in diverse PCa patients, including younger populations often excluded from national datasets. This approach supports more accurate survivorship research and can inform predictive modeling to guide patient counseling and treatment planning.
引用
- Woodle T, Hebert K, Kurtzman JT, et al. Defining Long-term Prostate Cancer Treatment Patterns and Adverse Urologic Events: A Methodological Framework and Patient Outcomes Using the Utah Population Database. Urology. 2025. PMID: 41352376. doi:10.1016/j.urology.2025.11.256
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。